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Abstract
Background/Aim. Early assessment of severity and con-
tinuous monitoring of patients are the key factors for ade-
quate treatment of acute pancreatitis (AP). The aim of this
study was to determine the value of procalcitonin (PCT) and
Bedside Index for Severity in Acute Pancreatitis (BISAP)
scoring system as prognostic markers in early stages of AP
with comparison to other established indicators such as C-
reactive protein (CRP) and Acute Physiology and Chronic
Health Evaluation (APACHE) II score. Methods. This pro-
spective study included 51 patients (29 with severe AP). In
the first 24 h of admission in all patients the APACHE II
score and BISAP score, CRP and PCT serum concentrations
were determined. The values of PCT serum concentrations
and BISAP score were compared with values of CRP serum
concentrations and APACHE II score, in relation to the se-
verity and outcome of the disease. Results. Values of PCT,
CRP, BISAP score and APACHE II score, measured at 24 h
of admission, were significantly elevated in patients with se-
vere form of the disease. In predicting severity of AP at 24 h
of admission, sensitivity and specificity of the BISAP score
were 74% and 59%, respectively, APACHE II score 89% and
69%, respectively, CRP 75% and 86%, respectively, and PCT
86% and 63%, respectively. It was found that PCT is highly
significant predictor of the disease outcome (p < 0,001).
Conclusion. In early assessment of AP severity, PCT has
better predictive value than CRP, and similar to the
APACHE II score. APACHE II score is a stronger predictor
of the disease severity than BISAP score. PCT is a good pre-
dictor of AP outcome.
Key words:
pancreatitis, acute necrotizing; severity of illness index;
prognosis; apache; treatment outcome.
Apstrakt
Uvod/Cilj. Rana procena težine i kontinuirano praýenje
bolesnika sa akutnim pankreatitisom (AP) osnovni su pre-
duslovi za adekvatno leÿenje. Cilj rada bio je da se odredi
znaÿaj prokalcitonina (PCT) i Bedside Index for Severity in
Acute Pancreatitis (BISAP) skoring sistema kao prognostiÿ-
kih parametara u ranoj fazi AP u poreĀenju sa ostalim po-
znatim indikatorima kao što su C-reaktivni protein (CRP) i
Acute Physiology and Chronic Health Evaluation (APACHE II)
score. Metode. Ova prospektivna studija obuhvatila je 51
bolesnika (29 sa teškim oblikom AP). U prva 24 sata od
prijema kod svih bolesnika odreĀen je APACHE II skor,
BISAP skor, i koncentracije CRP i PCT u serumu. Vred-
nosti koncentracija PCT u serumu i vrednosti BISAP sko-
ra uporeĀivane su sa vrednostima koncentracija CRP u se-
rumu i APACHE II skora, u odnosu na težinu i ishod bo-
lesti. Rezultati. Vrednosti PCT, CRP, BISAP i APACHE
II skora, merene u prva 24 sata od prijema u bolnicu, bile
su statistiÿki znaÿajno povišene kod bolesnika sa teškim
oblikom bolesti. U proceni težine AP u prva 24 sata od
prijema, utvrĀene su vrednosti senzitivnosti i specifiÿnosti
za BISAP skor (74%; 59%), APACHE II skor (89%;
69%), CRP (75%; 86%) i PCT (86%; 63%). NaĀeno je da
je PCT visokoznaÿajan prediktor ishoda bolesti (p < 0,001)
Zakljuÿak. U ranoj proceni težine AP, PCT je bolji indi-
kator od CRP i sliÿan je APACHE II skoru. APACHE II
skor je jaÿi prediktor težine bolesti od BISAP skora. PCT
je dobar prediktor ishoda AP.
Kljuÿne reÿi:
pankreatitis, akutni, nekrotizujuýi; bolest, indeks
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Introduction
“Acute pancreatitis is the most terrible of all the ca-
lamities that occur in connection to the abdominal viscera.
The suddenness of its onset, the illimitable agony which ac-
companies it, and the mortality attendant upon it, render it
the most formidable of catastrophes.” (Moynihan, 1925) 
1
This quotation still remains true because AP is unpre-
dictable disease, while severity and outcome is difficult to
predict with relatively few effective therapeutic options. The
mortality rate of severe AP (SAP) is about 25%–50%,
mainly due to multiple organ failure (MOF) and infection of
the necrosis 
2, 3. Early identification of patients with SAP and
their continuous monitoring are essential for adequate and
timely treatment in order to prevent possible complications.
Several biochemical markers 
4, 5, radiological imaging pro-
cedures 
6–8, and multiple clinical and biochemical scores 
9–12
have been used to assess  severity and outcome of AP. An ideal
prognostic method should be simple, inexpensive, routinely
available and highly accurate. Such a method is not available
yet.
Procalcitonin (PCT) is a 116-amino acids propeptide of
calcitonin who has no known hormonal activity, and can be
detected in high concentrations in serum during severe bacte-
rial or fungal but not viral infections 
13–15. It is synthesized and
secreted by the inflammatory and hepatic cells in response to
proinflammatory mediators. PCT was introduced as an early
marker of the systemic inflammatory response, sepsis, and
MOF. Further, increased serum concentration levels of PCT
have been suggested to be a reliable early predictor of a severe
outcome and infected pancreatic necrosis 
15–18.
In a recent multicentric cohort study a new prognostic
scoring system, so-called Bedside Index for Severity in
Acute Pancreatitis (BISAP), for prediction of mortality of
AP was proposed 
19. Using blood urea nitrogen (BUN) level
> 25 mg/dL, impaired mental status, systemic inflamatory re-
sponse syndrome (SIRS), age > 60 years and pleural effusion
in patients with AP, investigators were able to stratify pa-
tients within the first 24 hours of hospitalisation into distinct
risk groups for in hospital mortality. These authors 
19 pre-
sented BISAP score as an accurate scoring system in predic-
tion of the outcome of AP, such as Acute Physiology and
Chronic Health Evaluation (APACHE) II score.
The aim of this study was to assess the value of serum
PCT concentrations and value of BISAP score as prognostic
markers of severity of AP in early stages of AP in comparison
with CRP and APACHE II score, as well as to estimate the
value of PCT and BISAP score as predictors of AP outcome.
Methods
The study included of 51 consecutive patients with AP
admitted to the Clinic for Abdominal and Endocrine Sur-
gery, Military Medical Academy, Belgrade, Serbia, over a
14-month period (from June 2009 to September 2010). In
all patients, the diagnosis of AP was established in the first
three hours of admission by the presence of typical clinical
symptoms for AP, serum concentrations of amylase and/or
lipase above three times from the upper limit, and/or ra-
diological evidence compatible with AP. The patients with
confirmed AP were admitted to our hospital as primary or
secondary referrals within 48 h after the onset of the
symptoms and prospectively analyzed. The clinical course
of patients was followed prospectively until discharge or
death, with retrospective categorization into patients with
mild AP (MAP) and severe form of the disease according
to the Atlanta classification 
20. Ultrasonography was per-
formed within 12 h of admission and contrast enhanced
computed tomographic (CT) scan was performed according
to the United Kingdom guidelines for the management of
AP 
21. Serum CRP concentration levels were measured us-
ing a quantitatively immunoassay method (Cardio Phase,
hsCRP BN2, Siemens, Germany) on admission, and 24 h
and 48 h after admission. Serum levels of CRP determined
at 24 h of admission with the cut-off value of 120 mg/L
were accepted as an indicator for severe inflammation, as
reported in previous studies 
13, 22, 23. PCT serum concentra-
tion levels were measured with a commercial quantitative
assay (PCT sensitive, Kryptor, Brahms, Berlin, Germany)
on admission, at 24 h and 48 h after admission, at the 8th
and 10th hospital days and one more time in the 4th week
of the disease. Serum concentrations of PCT measured at
24 h of admission were included in this study. In this study
the value of APACHE II score calculated at 24 h of admis-
sion with the cut-off level of 8 and more was an accepted
level indicator for severe inflammation, as reported in pre-
vious studies 
20, 22, 24. The BISAP score was calculated at 24
h of admission using BUN level > 25 mg/dL, impaired
mental status, Systemic Inflammcetory Responsed Syn-
drome (SIRS), age > 60 years and pleural effusion (on
chest radiography or CT) 
25, 26. Altered mental status was
defined as any record of disorientation, lethargy somno-
lence, coma or stupor in the medical record 
27. The SIRS 
28,
29 was defined by the presence of 2  of the following crite-
ria: pulse > 90 beats/min; respirations > 20/min or PaCO2
< 32 mm Hg; body temperature > 38°C or < 36°C; white
blood cells (WBC) count >12 000 or < 4000 cells/mm3 or
>10% immature neutrophils (bands). Each point on the
BISAP score worth 1 point 
19,30, as presented in Table 1.
The values of APACHE II score and BISAP score calcu-
lated at 24 h of admission were included in this study. Sta-
tistical analysis was performed using the SPSS software
(Statistical package for the social sciences version 15.0,
Chicago, IL, USA). The patients were divided into two
groups according to severity and the outcome. Receiver op-
erating characteristic (ROC) curves and the respective areas
under the curves (AUC) were calculated. The diagnostic
performances of the different parameters were further as-
sessed by calculating sensitivity and specificity. Mann-
Whitney U-test was used to test significance between the
two groups. Z-test and Chi-square test were used to assess
the value of the respective parameters as indicators of the
disease severity and outcome. Z-test was further used to
test differences between BISAP score and APACHE II
score in early prediction of the AP severity. The results
were expressed as median followed by the range, and mean
followed by standard deviation (SD). Probability values
less than 0.05 were considered as statistically significant,
and probability values less than 0.001 were considered as
highly statistically significant.Volumen 69, Broj 5 VOJNOSANITETSKI PREGLED Strana 427
Bezmareviý M, et al. Vojnosanit Pregl 2012; 69(5): 425–431.
Results
A total of 51 patients, 34 (66.7%) males and 17 (33.3%)
females, with the median age of 61 years (range 19–83) were
included. Thirty-five patients (69%) were admitted within 0–
12 h of symptoms onset, 5 (10%) within 12–24 h and 11
(21%) of patients within 24–48 h of symptom onset. Etiology
was biliary in 28 (55%), alcoholic in 11 (21%), hyperlipide-
mia in 6 (12%), post endoscopic retrograde cholangiopan-
creatography (ERCP) pancreatitis in 1 (2%), pancreatic tu-
mor in 1 (2%) and of unknown cause in 4 (8%) patients. The
values of the prognostic markers at 24 h of admission are
listed in Table 2.
Twenty-two (43%) patients fully recovered and were
classified into the group with MAP. Twenty-nine (57%) pa-
tients developed significant complications and were classi-
fied in the group with severe form of the disease. Seventeen
of 29 patients with SAP had local complications. All patients
with SAP had an organ failure of one or more organ systems
during hospitalization. Overall mortality rate was 18% (9
patients), and 31% (9 patients) was in patients with SAP.
Four patients died in the first week as a result of MOF, and
the remaining 5 patients developed an organ failure (one or
more organ systems) in addition to local complications.
The APACHE II scores calculated at 24 h of admission,
and serum concentration of CRP and PCT values measured at
24 hours of admission were highly significantly higher in pa-
tients with SAP than in patients with MAD (p < 0.001). The
BISAP scores calculated at 24 h of admission were signifi-
cantly higher in the patients with SAP than those with mild
attacks (p = 0.008, Z = -2.668). ROC curves for the observed
values of BISAP and APACHE II score at 24 h of admission
are shown in Figure 1, and sensitivity and specificity for the
respective values are presented in Table 3.
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Fig. 1 – ROC curves for the BISAP and APACHE II score calcu-
lated at 24 h of admission in patients with acute pancreatitis
ROC – receiver operating characteristic, APACHE II – Acute Physiology and
Chronic Health Evaluation II, Sn – Sensitivity; 1-Sp – Specificity,  BISAP –
Bedside Index for Severity in Acute Pancreatitis
Table 1
The Bedside Index for Severity in Acute Pancreatitis (BISAP) scoring system
 19, 30
Blood urea nitrogen >25 (mg/dL)
Impaired mental status disorientation, lethargy somnolence,
coma or stupor
SIRS (Systemic Inflammatory Response Syndrome)
Age > 60 years
Pleural effusion (on chest radiography or computed tomography)
- Each point on the BISAP score worth 1 point
Observed mortality risk with an increasing number of points: 
30
` 0 point: mortality rate of 0.1%
` 1 point: mortality rate of 0.4%
` 2 points: mortality rate of 1.6%
` 3 points: mortality rate of 3.6%
` 4 points: mortality rate of 7.4%
` 5 points: mortality rate of 9.5%
Table 2
The values of the prognostic markers of acute pancreatitis (AP) at 24 h of admission
Parameters AP N Mean Median Minimum Maximum Range SD
Severe 29 15.79 16.00 7 23 16 4.701
Mild 22 7.95 7.50 6 14 8 1.838 APACHE II score 
a
Total 51 12.41 10.00 6 23 17 5.401
Severe 29 161.45 160.00 67 332 265 63.138
Mild 22 74.64 75.00 13 166 153 44.841 C-reactive protein
(mg/L) 
a
Total 51 124.00 112.00 13 332 319 70.445
Severe 29 2.5072 0.7500 0.09 34.66 34.57 6.73732
Mild 22 0.2600 0.2250 0.05 0.87 0.82 0.20281 Procalcitonin
(ng/mL) 
a, b
Total 51 1.5378 0.3600 0.05 34.66 34.61 5.16721
Severe 29 3.2759 4.0000 1.00 5.00 4.00 0.95978
Mild 22 2.4545 2.0000 1.00 4.00 3.00 1.05683 BISAP score 
c
Total 51 2.9216 3.0000 1.00 5.00 4.00 1.07412
a Mann-Whitney U test, p <  0.001;  
b Chi-square test, p < 0.001; 
c Z-test, p = 0.008.
N – number of patients, SD –  standard deviation, APACHE II – Acute physiology and chronic health  evaluation II
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In testing differences between the BISAP score and
APACHE II score (difference between AUC of respective pa-
rameters), and their strengths to predict a severe form of AP
with accuracy, APACHE II score was significantly stronger
predictor of disease severity than BISAP score (Table 4).
The values distribution of APACHE II score, BISAP
score, CRP and PCT noted at 24 h of admission in survivors
and nonsurvivos are presented in Figure 2.
Table 4
Differences in the strenghts of respective parameters to predict severe form
of acute pancreatitis
Parameters CRP PCT BISAP score
APACHE II score Z = 0.969; p = 0.332 Z = 0.830; p = 0.111 Z=2.738; p = 0.006
C-reactive protein Z = 0.630; p = 0.528 Z=1.882; p = 0.059
Procalcitonin Z=1.302; p = 0.193
Z – Z-test, APACHE II – Acute Physiology and Chronic Health Evaluation II score;
BISAP – Bedside Index for Severity in Acute Pancreatitis
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Fig. 2 –  Distribution of values of APACHE II score, BISAP score, C – reactive protein,
(CRP) and procalcitonin (PCT) noted at 24 h of admission in survivors and nonsurvivos
APACHE II – Acute Physiology and Chronic Health Evaluation II; BISAP – Bedside Index for Severity in Acute
Pancreatitis
Table 3
Ability of prognostic markers measured at 24 h of admission to predict acute pancreatitis (AP) severity
Asymptotic 95% Confi-
dence Interval Test result
variable(s) AUC SE p value Lower
Bound Upper Bound
Cut off Sensitivity Specificity
APACHE II score 0.933 0.034 0.000 0.867 1.000 8 0.89 0.69
C-reactive protein 0.876 0.048 0.000 0.783 0.969 120 mg/L 0.75 0.86
Procalcitonin 0.830 0.055 0.000 0.721 0.939 0.25 ng/mL 0.86 0.63
BISAP score 0.710 0.074 0.011 0.565 0.855 3 0.74 0.59
AUC – Area under curve; SE – standard error, APACHE II – Acute Physiology and Chronic Health Evaluation II, BISAP – Bedside Index for Se-
verity in Acute PancreatitisVolumen 69, Broj 5 VOJNOSANITETSKI PREGLED Strana 429
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Between survivors and nonsurvivors there was a signifi-
cant difference in APACHE II scores (Chi-square=9.222, p =
0.002; Z=-2.891, p = 0.004), BISAP scores (Z=-2.975, p =
0.003) and serum values of CRP (Chi-square=6.317, p  =
0.012; Z=-2.434, p = 0.015), and a highly significant differ-
ence in serum concentrations of PCT (Chi-square=23.592, p <
0.001; Z=-4.177, p < 0.001) registered in 24 h of admission.
In serial measurements of serum concentrations of PCT
it was registered that the most patients had maximal serum
values of PCT noted in the first few days of hospitalization.
The highest measured concentration values of PCT during
hospitalization were significantly higher in nonsurvivors than
survivors (Chi-square 33.157; p < 0.001).
Discussion
Early assessment of AP severity is essential for ade-
quate and timely treatment. Moreover, it helps in reducing
the mortality rate and can help in preventing numerous com-
plications during the course of the disease. The scoring sys-
tems and biochemical markers which are being used for as-
sessment of severity are also helpful for continuous moni-
toring of patients with AP. Although evaluation of AP sever-
ity demands a lot of procedures which are usually expensive,
it can indirectly reduce a duration of hospital stay and im-
prove cost benefit of the treatment. In this study, we investi-
gated the value of PCT and BISAP score for prediction of
severity and outcome in patients with AP. The predictive
values were compared to the traditional biochemical marker
and scoring system rutinely used in clinical practice, such as
CRP and APACHE II score.
The APACHE II severity of the disease scoring system
can be performed at admission and daily to help in identify-
ing patients with SAP 
22, 24, 31. A variety of reports have cor-
related a higher APACHE II score at admission and during
the first 72 h with a severe form of the disease and higher
mortality rate. The sensitivity, specificity, as well as positive
and negative predictive values ranges between 65%–81%,
77%–91%, 23%–69% and 86%–99%, respectively, have
been reported 
22, 32, 33. Our results are similar to other studies.
Agarwal et al. 
34 reported that one of the potential weak-
nesses of APACHE II score is the fact that in patients older
than 65 years there is a higher possibility of a false-positive
score. We found that APACHE II score was highly signifi-
cantly higher in patients with SAP than in patients with
MAP. Also, APACHE II score in our study was significantly
higher in nonsurvivors than survovors noted at 24 h of ad-
mission.
In the mid-1980s, several studies showed that the hepatic
production of CRP was increased after any type of inflamma-
tion, and subsequently the protein was proposed as a prognos-
tic factor in AP 
2, 5, 7, 13. Several investigators evaluated this
marker as a predictor for severity when it was measured on
admission, and in 24, 48 or 72 h after admission, and em-
ployed variable cut-off levels ranged between 110 mg/L and
150 mg/L 
13. With the CRP cut-off value of 115 mg/L meas-
ured at 24 h after admission Chen et al 
35 reported the sensitiv-
ity of 44% and specificity of 96% in prediction of severity of
AP. Leser et al. 
36 reported the sensitivity and specificity rate
of 67% and 79% for CRP as a predictor of severity of AP
measured in 24/48 h after admission with the cut-off value of
100 mg/L. Just a few reports evaluated value of CRP as a pre-
dictor of severity of AP at 24 h of admission with the cut-off
value of 120 mg/L 
37, 38, but without exactly noted time of on-
set of symptoms or noted values of sensitivity and specificity.
A possible flaw of this marker is the fact that it reaches its
peak only after 36–72 h after admission, and the results of this
test may not be entirely reliable at admission in assessing the
severity of disease 
39, 40. As compared with other studies, we
found a high sensitivity, but lower specificity in our research.
Such finding could be a result of later appearance of the peak
values. In our study serum concentration of CRP was highly
significantly higher in patients with SAP, and significantly
higher in nonsurvivors than survivors, registered at 24 h of
admission.
The actual pathophysiologic role of PCT is still under
investigation, and it was assumed that PCT might be also an
acute phase protein  
40. In SIRS, regardless of the cause, the
first released cytokines are tissue necrosis factor-alpha
(TNF-a) and interleukin (IL)-1. Under their influence, the
production of other proinflammatory cytokines such as IL-6,
IL-8 and interferon gamma starts. These cytokines, espe-
cially IL-6, stimulate the release of CRP and PCT 
41–43. This
is an indirect way of excretion, while the release of PCT is
primarly induced via microbial toxins (eg endotoxin)
 44.
Those various stimuli increase gene expression, which is re-
sponsible for secretion of PCT, and constitutive release of
PCT from all parenchymal tissues and differentiated cell
types throughout the body, including the liver, kidney, adi-
posities and muscle 
45. Serum concentrations of PCT was
evaluated for its utility as predictor of severity and outcome
of the AP in several studies 
17, 46–51. The predictive value of
PCT in our study was comparable to the results of Kylanapa-
Back et al. 
17. In the study of these investigators its sensitiv-
ity and specificity were 92% and 84%, respectively, with the
cut-off value of 0.5 ng/mL. In our study these values were
86% and 63%, but with much lower cut-off value, such as
0.25 ng/mL. Pindak et al.
 48 found that at 12 h after admis-
sion value of PCT was better than value of CRP in predicting
the course and fatal outcome of the disease. In our study, the
concentrations of PCT measured at 24 h of admission were
highly significantly higher in nonsurvivors than survivors.
Also, PCT levels measured at 24 h of admission were highly
significantly higher in patients with SAP than in patients
with MAP. While PCT was an excellent predictor of dis-
ease's course and fatal outcome, the serum levels of CRP
measured at 24 h of admission were good predictor of dis-
ease’s course but not so good in predicting fatal outcome in
AP. Confirmation for the fact that elevated serum concentra-
tions of PCT can be found in acute inflammation, not only in
infectious conditions, is that the maximal recorded PCT val-
ues were in the first few days of hospitalization in the most
of patients, when there was relatively small possibility for
pancreatic infection.
The most commonly utilised prediction scoring system
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the APACHE II score it requires the collection of a large num-
ber of parameters. An optimal scoring system for predicting
severity and outcome of AP should be simple, accurate and
able to be calculated in the first 24 h of hospitalization. With
the usage of population-based data researchers from the United
States developed and presented BISAP score, as a very simple
and easy to use 
19. In addition, they cited that each of the pa-
rameters in BISAP score can be easily obtained early in the
course of hospital admission. In the study of these authors
there was no significant difference in the predictive accuracy
between the BISAP score and the APACHE II score; in sub-
group analysis, the BISAP score was effective in predicting
mortality rates in patients without the evidence of early organ
failure, and BISAP score was able to achieve a similar level of
predictive accuracy to the more complex APACHE II score,
with far fewer variables. We found that the APACHE II score
was a better predictor of AP severity than BISAP score with
sensitivity of 89% and specificity of 69%, while the BISAP
score had specifity of 74%, asnd sensitivity of 59%. Further,
with much greater AUC the APACHE II score was signifi-
cantly stronger predictor of the disease severity than BISAP
score (Z=2.738; p = 0.006). The value of the BISAP score in
early prediction of AP mortality was similar to the APACHE
II score. A possible explanation of why the BISAP score had
lower ability to predict SAP than APACHE II score is because
our study included a smaller number of patients then the study
of authors from the United States  
19. Although difficult to per-
form, APACHE II score is multipoint system and provides a
more objective clinical picture in patients with AP. Anyway,
due to simplicity and easily obtained parameters, BISAP score
should gain broad acceptance in routine use not by replacing
clinical assessment, but rather by complementing and objecti-
fying it.
Conclusion
In early prediction of AP severity, PCT has a better
predictive value than CRP, and similar predictive value as
the APACHE II score. PCT is a better predictor of fatal out-
come in AP measured at 24 h of admission than CRP, BISAP
score and APACHE II score. APACHE II score is a stronger
predictor of disease severity than BISAP score. In early pre-
diction of AP outcome, BISAP score has similar value to the
APACHE II score. PCT analysis is simple, routinely avail-
able and a highly accurate method in early assessment of AP
severity and outcome.
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